Recursion Pharmaceuticals, Inc. Class A Common Stock
Here’s whether Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 57 — healthy momentum range; 3-month momentum positive (+7.8%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.40% over 10 days); weak 1-year return of -44.0%. Currently 56.0% off its 52-week high. Score: -3/7.
RXRX is trading below its 200-day MA ($3.76) — a key warning sign the longer-term trend is under pressure. An RSI of 56.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -44.0% compares to +20.4% for SPY (trailed the market by 64.3%). The current 56.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.